Research programme: bicycle oligonucleotide therapeautics - Bicycle Therapeutics
Latest Information Update: 18 Apr 2022
At a glance
- Originator Bicycle Therapeutics
- Developer Bicycle Therapeutics; Ionis Pharmaceuticals
- Class Drug conjugates; Oligonucleotides; Small molecules
- Mechanism of Action Transferrin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuromuscular disorders